Alkermes plc has completed patient enrollment in the pivotal, multinational Phase III study evaluating aripiprazole lauroxil in patients with schizophrenia. Aripiprazole lauroxil is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY®. Alkermes continues to expect topline results from the study in the first half of 2014. Enrollment was completed following a pres...